Clinicopathological characteristics comprising patients’ age, sex, tumor diameter, tumor stage, metastatic status, and invasive status
| . | Total . | Benign . | Malignant . |
|---|---|---|---|
| Age, y | |||
| < 55 | 60 (67.4%) | 12 (13.5%) | 48 (53.9%) |
| ≥ 55 | 29 (32.6%) | 9 (10.1%) | 20 (22.5%) |
| Sex | |||
| Male | 26 (29.2%) | 3 (3.4%) | 23 (25.8%) |
| Female | 63 (70.8%) | 18 (20.2%) | 45 (50.6%) |
| Tumor diameter, cm | |||
| ≤ 3 | 57 (64%) | – | 57 (64%) |
| > 3 | 11 (12.4%) | – | 11 (12.4%) |
| Tumor stage | |||
| I | 42 (47.2%) | – | 42 (47.2%) |
| II | 19 (21.3%) | – | 19 (21.3%) |
| III | 1 (1.1%) | – | 1 (1.1%) |
| IV | 6 (6.7%) | – | 6 (6.7%) |
| Metastasis | |||
| Free | 26 (29.2%) | – | 26 (29.2%) |
| Lymph node | 22 (24.7%) | – | 22 (24.7%) |
| Distant | 20 (22.5%) | – | 20 (22.5%) |
| Invasiveness | |||
| Noninvasive | 36 (40.4%) | – | 36 (40.4%) |
| Mini-invasive | 19 (21.3%) | – | 19 (21.3%) |
| Invasive | 13 (14.6%) | – | 13 (14.6%) |
| . | Total . | Benign . | Malignant . |
|---|---|---|---|
| Age, y | |||
| < 55 | 60 (67.4%) | 12 (13.5%) | 48 (53.9%) |
| ≥ 55 | 29 (32.6%) | 9 (10.1%) | 20 (22.5%) |
| Sex | |||
| Male | 26 (29.2%) | 3 (3.4%) | 23 (25.8%) |
| Female | 63 (70.8%) | 18 (20.2%) | 45 (50.6%) |
| Tumor diameter, cm | |||
| ≤ 3 | 57 (64%) | – | 57 (64%) |
| > 3 | 11 (12.4%) | – | 11 (12.4%) |
| Tumor stage | |||
| I | 42 (47.2%) | – | 42 (47.2%) |
| II | 19 (21.3%) | – | 19 (21.3%) |
| III | 1 (1.1%) | – | 1 (1.1%) |
| IV | 6 (6.7%) | – | 6 (6.7%) |
| Metastasis | |||
| Free | 26 (29.2%) | – | 26 (29.2%) |
| Lymph node | 22 (24.7%) | – | 22 (24.7%) |
| Distant | 20 (22.5%) | – | 20 (22.5%) |
| Invasiveness | |||
| Noninvasive | 36 (40.4%) | – | 36 (40.4%) |
| Mini-invasive | 19 (21.3%) | – | 19 (21.3%) |
| Invasive | 13 (14.6%) | – | 13 (14.6%) |
Clinicopathological characteristics comprising patients’ age, sex, tumor diameter, tumor stage, metastatic status, and invasive status
| . | Total . | Benign . | Malignant . |
|---|---|---|---|
| Age, y | |||
| < 55 | 60 (67.4%) | 12 (13.5%) | 48 (53.9%) |
| ≥ 55 | 29 (32.6%) | 9 (10.1%) | 20 (22.5%) |
| Sex | |||
| Male | 26 (29.2%) | 3 (3.4%) | 23 (25.8%) |
| Female | 63 (70.8%) | 18 (20.2%) | 45 (50.6%) |
| Tumor diameter, cm | |||
| ≤ 3 | 57 (64%) | – | 57 (64%) |
| > 3 | 11 (12.4%) | – | 11 (12.4%) |
| Tumor stage | |||
| I | 42 (47.2%) | – | 42 (47.2%) |
| II | 19 (21.3%) | – | 19 (21.3%) |
| III | 1 (1.1%) | – | 1 (1.1%) |
| IV | 6 (6.7%) | – | 6 (6.7%) |
| Metastasis | |||
| Free | 26 (29.2%) | – | 26 (29.2%) |
| Lymph node | 22 (24.7%) | – | 22 (24.7%) |
| Distant | 20 (22.5%) | – | 20 (22.5%) |
| Invasiveness | |||
| Noninvasive | 36 (40.4%) | – | 36 (40.4%) |
| Mini-invasive | 19 (21.3%) | – | 19 (21.3%) |
| Invasive | 13 (14.6%) | – | 13 (14.6%) |
| . | Total . | Benign . | Malignant . |
|---|---|---|---|
| Age, y | |||
| < 55 | 60 (67.4%) | 12 (13.5%) | 48 (53.9%) |
| ≥ 55 | 29 (32.6%) | 9 (10.1%) | 20 (22.5%) |
| Sex | |||
| Male | 26 (29.2%) | 3 (3.4%) | 23 (25.8%) |
| Female | 63 (70.8%) | 18 (20.2%) | 45 (50.6%) |
| Tumor diameter, cm | |||
| ≤ 3 | 57 (64%) | – | 57 (64%) |
| > 3 | 11 (12.4%) | – | 11 (12.4%) |
| Tumor stage | |||
| I | 42 (47.2%) | – | 42 (47.2%) |
| II | 19 (21.3%) | – | 19 (21.3%) |
| III | 1 (1.1%) | – | 1 (1.1%) |
| IV | 6 (6.7%) | – | 6 (6.7%) |
| Metastasis | |||
| Free | 26 (29.2%) | – | 26 (29.2%) |
| Lymph node | 22 (24.7%) | – | 22 (24.7%) |
| Distant | 20 (22.5%) | – | 20 (22.5%) |
| Invasiveness | |||
| Noninvasive | 36 (40.4%) | – | 36 (40.4%) |
| Mini-invasive | 19 (21.3%) | – | 19 (21.3%) |
| Invasive | 13 (14.6%) | – | 13 (14.6%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
